{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:40:03Z","timestamp":1792726803597,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cmi.2026.07.036","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:50:12Z","timestamp":1785394212000},"page":"1789-1796","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["How do I screen for tuberculosis and provide tuberculosis preventive treatment in people with HIV?"],"prefix":"10.1016","volume":"32","author":[{"given":"Angelo Roberto","family":"Raccagni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta Maria","family":"Antonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margherita","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Calcagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giacomelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Riccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2026.07.036_bib1","series-title":"Global tuberculosis report 2025","year":"2025"},{"key":"10.1016\/j.cmi.2026.07.036_bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/23744235.2023.2217912","article-title":"Tuberculosis in migrants: Epidemiology, resistance and outcome in Milan, Italy","volume":"55","author":"Riccardi","year":"2023","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.cmi.2026.07.036_bib3","article-title":"Spatiotemporal patterns and socioeconomic determinants of pulmonary tuberculosis in Dongguan city, China, during 2011-2020: An ecological study","volume":"14","author":"Zhang","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.cmi.2026.07.036_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1186\/s12879-019-4244-4","article-title":"Interaction of nutritional status and diabetes on active and latent tuberculosis: A cross-sectional analysis","volume":"19","author":"Kubiak","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0127-2022","article-title":"A scoping review on the risk of tuberculosis in specific population groups: Can we expand the World Health Organization recommendations?","volume":"32","author":"Bigio","year":"2023","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.cmi.2026.07.036_bib8","series-title":"Global tuberculosis report 2020","year":"2020"},{"key":"10.1016\/j.cmi.2026.07.036_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2025.107892","article-title":"World TB Day 2025 Theme \"Yes! We Can End TB: Commit, Invest, Deliver\" can be made a reality through concerted global efforts to advance diagnosis, treatment and research of tuberculosis infection and disease","volume":"155","author":"Goletti","year":"2025","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/j.cmi.2025.04.020","article-title":"Treatment of tuberculosis infection-not just a question of efficacy and toxicity","volume":"31","author":"Zenner","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.036_bib11","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1016\/j.ijid.2023.02.016","article-title":"Programmatic management of tuberculosis preventive therapy: Past, present, future","volume":"130","author":"Matteelli","year":"2023","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2020.102041","article-title":"Missed opportunities in tb clinical practice: How to bend the curve? A medical, social, economic and ethical point of view","volume":"126","author":"Riccardi","year":"2021","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.cmi.2026.07.036_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02174-2023","article-title":"Tuberculosis preventive treatment care pathways in people living with HIV: A systematic review and meta-analysis","volume":"66","author":"Degtyareva","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2026.07.036_bib14","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5588\/ijtld.21.0753","article-title":"Clinical standards for the diagnosis, treatment and prevention of TB infection","volume":"26","author":"Migliori","year":"2022","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib15","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmi.2023.02.016","article-title":"Treatment of latent tuberculosis infection in incarcerated people: A systematic review","volume":"29","author":"Matucci","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.036_bib17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"211","author":"Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2026.07.036_bib18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa","volume":"377","author":"Hakim","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.036_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161983","article-title":"The clinical usefulness of tuberculin skin test versus interferon-gamma release assays for diagnosis of latent tuberculosis in HIV patients: A meta-analysis","volume":"11","author":"Ayubi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2026.07.036_bib20","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S1473-3099(20)30276-0","article-title":"Interferon-\u03b3 release assays or tuberculin skin test for detection and management of latent tuberculosis infection: A systematic review and meta-analysis","volume":"20","author":"Zhou","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae479","article-title":"Primary care guidance for providers who care for persons with Human Immunodeficiency Virus: 2024 update by the HIV Medicine Association of the Infectious Diseases Society of America","author":"Horberg","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib22","doi-asserted-by":"crossref","first-page":"e518","DOI":"10.1016\/j.ijid.2012.03.002","article-title":"Risk factors for tuberculin skin test conversion among HIV-infected patients in New York City","volume":"16","author":"Doshi","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib23","unstructured":"National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America Panel on Opportunistic Infections in Adults and Adolescents With HIV\u2014 A Working Group of the Office of AIDS Research Advisory Council (OARAC). Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. [Updated 2026 May 27]. In: ClinicalInfo.HIV.gov [Internet]. Rockville (MD): US Department of Health and Human Services; 2002. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK586304\/."},{"key":"10.1016\/j.cmi.2026.07.036_bib24","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1016\/S2352-3018(18)30137-1","article-title":"Sensitivity and specificity of WHO's recommended four-symptom screening rule for tuberculosis in people living with HIV: A systematic review and meta-analysis","volume":"5","author":"Hamada","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2026.07.036_bib25","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx123","article-title":"Diagnostic outcomes after chest radiograph interpretation in patients with suspected tuberculosis and negative sputum smears in a high-burden human immunodeficiency virus and tuberculosis setting","volume":"4","author":"Cudahy","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib26","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1016\/j.jacr.2017.02.022","article-title":"ACR Appropriateness criteria imaging of possible tuberculosis","volume":"14","author":"Expert Panel on Thoracic Imaging","year":"2017","journal-title":"J Am Coll Radiol"},{"key":"10.1016\/j.cmi.2026.07.036_bib27","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(18)31267-4","article-title":"Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): A pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial","volume":"392","author":"Gupta-Wright","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.07.036_bib28","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJMra2308181","article-title":"HIV-associated tuberculosis","volume":"391","author":"Meintjes","year":"2024","journal-title":"N Engl J Med."},{"key":"10.1016\/j.cmi.2026.07.036_bib29","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2666-5247(22)00062-3","article-title":"Xpert ultra testing of blood in severe HIV-associated tuberculosis to detect and measure Mycobacterium tuberculosis blood stream infection: A diagnostic and disease biomarker cohort study","volume":"3","author":"Boloko","year":"2022","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.cmi.2026.07.036_bib30","article-title":"Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV","volume":"10","author":"Bjerrum","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2026.07.036_bib31","first-page":"CD014641","article-title":"Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV","volume":"8","author":"Nathavitharana","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2026.07.036_bib32","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cmi.2022.06.022","article-title":"Diagnostic toolkit for tuberculosis: Should we include urine lipoarabinomannan (LAM) detection in the WHO European Region?","volume":"28","author":"Kraef","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.036_bib33","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","article-title":"Isoniazid plus antiretroviral therapy to prevent tuberculosis: A randomised double-blind, placebo-controlled trial","volume":"384","author":"Rangaka","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2026.07.036_bib34","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2352-3018(20)30299-X","article-title":"Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: A systematic review and meta-analysis of individual participant data","volume":"8","author":"Ross","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2026.07.036_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0330208","article-title":"Effectiveness of tuberculosis preventive treatment on disease incidence among people living with HIV\/AIDS: A systematic review and meta-analysis","volume":"20","author":"Silva J\u00fanior","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2026.07.036_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003738","article-title":"Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis","volume":"18","author":"Yanes-Lane","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.cmi.2026.07.036_bib37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13690-023-01098-z","article-title":"Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: A systematic review and network meta-analysis of randomized controlled trials","volume":"81","author":"Assefa","year":"2023","journal-title":"Arch Public Health"},{"key":"10.1016\/j.cmi.2026.07.036_bib38","article-title":"Tuberculosis and pharmacological interactions: A narrative review","volume":"2","author":"Riccardi","year":"2020","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.cmi.2026.07.036_bib39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/phar.2672","article-title":"Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management","volume":"42","author":"MacDougall","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2026.07.036_bib40","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/17425255.2018.1416093","article-title":"Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: A tool for treatment optimization?","volume":"14","author":"Motta","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.cmi.2026.07.036_bib41","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archinte.162.9.985","article-title":"Rifampin and rifabutin drug interactions: An update","volume":"162","author":"Finch","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cmi.2026.07.036_bib42","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0000000000003810","article-title":"The Effect of rifampicin on the plasma and intracellular pharmacokinetics of tenofovir alafenamide fumarate in participants with HIV-associated tuberculosis","volume":"101","author":"Mpofu","year":"2026","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cmi.2026.07.036_bib43","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/cid\/ciae269","article-title":"Effectiveness of double-dose dolutegravir in people receiving rifampin-based tuberculosis treatment: An observational, cohort study of people with HIV from 6 countries","volume":"80","author":"Shah","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib44","first-page":"983","article-title":"Twice-daily dolutegravir-based antiretroviral therapy with 1 month of daily rifapentine and isoniazid for tuberculosis prevention","volume":"79","author":"Podany","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib45","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1473-3099(20)30869-0","article-title":"Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): An open-label, non-inferiority, randomised, phase 3 trial","volume":"21","author":"De Castro","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib46","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: A phase 1\/2 trial","volume":"7","author":"Dooley","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2026.07.036_bib47","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One Month of rifapentine plus isoniazid to prevent HIV-related tuberculosis","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2026.07.036_bib48","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2352-3018(25)00002-5","article-title":"Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: An open-label, non-randomised, phase 1\/2 trial","volume":"12","author":"Weld","year":"2025","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2026.07.036_bib49","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/S2352-3018(25)00200-0","article-title":"Fixed-dose combination bictegravir-emtricitabine-tenofovir alafenamide twice-daily for treatment of HIV during rifampicin-based tuberculosis treatment (INSIGHT Study): A phase 2b, open-label, randomised non-comparative trial","volume":"13","author":"Naidoo","year":"2026","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cmi.2026.07.036_bib50","series-title":"WHO operational handbook on tuberculosis Module 1: prevention - tuberculosis preventive treatment","year":"2024"},{"key":"10.1016\/j.cmi.2026.07.036_bib51","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.cmi.2025.12.017","article-title":"Noninvasive diagnosis of pulmonary tuberculosis using face mask sampling: A prospective study in adults","volume":"32","author":"Woelk","year":"2025","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2026.07.036_bib52","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2386030","article-title":"Biomarkers in diagnosing and therapeutic monitoring of tuberculosis: A review","volume":"56","author":"Leo","year":"2024","journal-title":"Ann Med"},{"key":"10.1016\/j.cmi.2026.07.036_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2026.108954","article-title":"In silico transcriptomic analysis for biomarker discovery in TB and HIV co-infection","volume":"123","author":"Aalam","year":"2026","journal-title":"Comput Biol Chem"},{"key":"10.1016\/j.cmi.2026.07.036_bib54","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/diseases14020066","article-title":"Detection for new biomarkers of tuberculosis infection activity using machine learning methods","volume":"14","author":"Starshinova","year":"2026","journal-title":"Diseases"},{"key":"10.1016\/j.cmi.2026.07.036_bib55","doi-asserted-by":"crossref","first-page":"910","DOI":"10.25259\/IJMR_1546_2025","article-title":"Artificial intelligence for screening drug resistance in tuberculosis","volume":"162","author":"Mohanvel","year":"2025","journal-title":"Indian J Med Res."},{"key":"10.1016\/j.cmi.2026.07.036_bib56","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/tropicalmed11020036","article-title":"AI-driven tuberculosis hotspot mapping to optimize active case-finding: Implementing the epi-control platform in Uganda","volume":"11","author":"Amanya","year":"2026","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.cmi.2026.07.036_bib57","doi-asserted-by":"crossref","first-page":"54553","DOI":"10.1021\/acsami.5c13207","article-title":"Strategic modulation of isoniazid solubility through cocrystal formation for long-acting microneedle therapy of tuberculosis","volume":"17","author":"Fandi\u00f1o","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.cmi.2026.07.036_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126103","article-title":"Development of highly concentrated bedaquiline suspensions for usage as long-acting injectable formulations","volume":"684","author":"Hansen","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.cmi.2026.07.036_bib59","doi-asserted-by":"crossref","first-page":"4455","DOI":"10.1038\/s41467-022-32043-3","article-title":"A long-acting formulation of rifabutin is effective for prevention and treatment of Mycobacterium tuberculosis","volume":"13","author":"Kim","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2026.07.036_bib60","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1164\/rccm.202012-4541OC","article-title":"Efficacy of long-acting bedaquiline regimens in a mouse model of tuberculosis preventive therapy","volume":"205","author":"Kaushik","year":"2022","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26004039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X26004039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:20:53Z","timestamp":1792725653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X26004039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":57,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S1198743X26004039"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2026.07.036","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How do I screen for tuberculosis and provide tuberculosis preventive treatment in people with HIV?","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2026.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}